Farudodstat is under clinical development by Aslan Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Farudodstat’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 17 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 17 Oct 2022 increased Farudodstat’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Farudodstat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Farudodstat overview

Farudodstat (ASLAN-003) is under development for the treatment of autoimmune skin disease such as alopecia areata, solid tumors like hepatocellular carcinoma, rheumatoid arthritis, triple negative breast cancer (TNBC), relapsed and refractory acute myeloid leukemia (AML), multiple sclerosis (MS) and liver infections. The drug candidate is administered orally. ASLAN-003 targets dihydroorotate dehydrogenase (DHODH). The drug candidate was also under development for the treatment of multiple sclerosis.

It was also under development for the treatment of inflammatory bowel disease.

Aslan Pharmaceuticals overview

Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore.

Quick View Farudodstat LOA Data

Report Segments
  • Innovator
Drug Name
  • Farudodstat
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.